Skip Navigation


Human Reproduction Update Advance Access first published online on March 27, 2006
This version published online on June 8, 2006
Human Reproduction Update, doi:10.1093/humupd/dml001
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
12/4/333    most recent
dml001v2
dml001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tarlatzis, B.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tarlatzis, B.C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received December 21, 2005
Accepted January 13, 2006

Article

GnRH antagonists in ovarian stimulation for IVF

B.C. Tarlatzis 1 *, B.C. Fauser 2, E.M. Kolibianakis 1, K. Diedrich 3, P. Devroey 4, and On Behalf of the Brussels GnRH Antagonist Consensus Workshop Group

1 Unit for Human Reproduction, 1st Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
2 Department of Reproductive Medicine and Gynaecology, University Medical Centre, Utrecht, Netherlands
3 Department of Gynecology and Obstetrics, Division of Gynaecological Endocrinology and Reproductive Medicine, University Clinic of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
4 Centre for Reproductive Medicine, Dutch-Speaking Brussels Free University, Brussels, Belgium

* To whom correspondence should be addressed.
B.C. Tarlatzis, E-mail: tarlatzis{at}hol.gr


  Abstract

The present review describes, on the basis of the currently available evidence, the consensus reached by a group of experts on the use of gonadotropin-releasing hormone (GnRH) antagonists in ovarian stimulation for IVF. The single or multiple low-dose administration of GnRH antagonist during the late-follicular phase effectively prevents a premature rise in serum luteinizing hormone (LH) levels in most women. Although controversy remains, most comparative studies suggest a slight, not significant reduction in the probability of pregnancy after IVF using GnRH antagonist versus GnRH agonist co-treatment. Published meta-analyses suggest that this slight difference in pregnancy rates is not attributed to chance. Further studies applying varying treatment regimens and outcome measures are required. Data are not in favour of a need to modify the starting dose of gonadotropins. Data are not in favour of increasing gonadotropin dose at GnRH antagonist initiation. The addition of LH from the initiation of ovarian stimulation or from GnRH antagonist administration does not appear to be necessary. Replacement of human chorionic gonadotropin (HCG) by GnRH agonist for triggering final oocyte maturation is associated with a lower probability of pregnancy. The optimal timing for HCG administration needs to be explored further. GnRH antagonist initiation on day 6 of stimulation appears to be superior to flexible initiation by a follicle of 14-16 mm, although earlier GnRH antagonist administration is worth further evaluation. Luteal phase supplementation in GnRH antagonist protocols remains mandatory in IVF. Effects of GnRH antagonist co-treatment on the incidence of ovarian hyperstimulation syndrome remains uncertain, although a trend is present in favour of the GnRH antagonists. The role of GnRH antagonists in ovarian stimulation for IVF appears to be promising, although many questions regarding preferred dose regimens and effects on clinical outcomes remain.

Keywords: GnRH antagonists/IVF/ovarian stimulation/pregnancy rates.

This version includes LJF Rombauts, Monash IVF, Clayton, Australia, Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia in the ‘Participant of the Brussels GnRH antagonist concensus workshop’


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
P. Devroey, R. Boostanfar, N.P. Koper, B.M.J.L. Mannaerts, P.C. IJzerman-Boon, B.C.J.M. Fauser, and on behalf of the ENGAGE Investigators
A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol
Hum. Reprod., December 1, 2009; 24(12): 3063 - 3072.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. Blockeel, M. De Vos, W. Verpoest, D. Stoop, P. Haentjens, and P. Devroey
Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study
Hum. Reprod., November 1, 2009; 24(11): 2910 - 2916.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
B.C.J.M. Fauser, B.M.J.L. Mannaerts, P. Devroey, A. Leader, I. Boime, and D.T. Baird
Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency
Hum. Reprod. Update, May 1, 2009; 15(3): 309 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
The ESHRE Capri Workshop Group
Intrauterine insemination
Hum. Reprod. Update, May 1, 2009; 15(3): 265 - 277.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
P. Devroey, M. Aboulghar, J. Garcia-Velasco, G. Griesinger, P. Humaidan, E. Kolibianakis, W. Ledger, C. Tomas, and B. C.J.M. Fauser
Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment
Hum. Reprod., April 1, 2009; 24(4): 764 - 774.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
M.F.G. Verberg, M.J.C. Eijkemans, N.S. Macklon, E.M.E.W. Heijnen, E.B. Baart, F.P. Hohmann, B.C.J.M. Fauser, and F.J. Broekmans
The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis
Hum. Reprod. Update, January 1, 2009; 15(1): 5 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
M.F.G. Verberg, N.S. Macklon, G. Nargund, R. Frydman, P. Devroey, F.J. Broekmans, and B.C.J.M. Fauser
Mild ovarian stimulation for IVF
Hum. Reprod. Update, January 1, 2009; 15(1): 13 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
The Corifollitropin Alfa Dose-finding Study Group
A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation
Hum. Reprod., November 1, 2008; 23(11): 2484 - 2492.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
N. S. Macklon, M. H. van der Gaast, A. Hamilton, B. C. J. M. Fauser, and L. C. Giudice
The Impact of Ovarian Stimulation With Recombinant FSH in Combination With GnRH Antagonist on the Endometrial Transcriptome in the Window of Implantation
Reproductive Sciences, April 1, 2008; 15(4): 357 - 365.
[Abstract] [PDF]

Home page
 Hum Reprod UpdateHome page
T.E.M. Verhagen, D.J. Hendriks, L.F.J.M.M. Bancsi, B.W.J. Mol, and F.J.M. Broekmans
The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis
Hum. Reprod. Update, March 1, 2008; 14(2): 95 - 100.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Polinder, E.M.E.W. Heijnen, N.S. Macklon, J.D.F. Habbema, B.J.C.M. Fauser, and M.J.C. Eijkemans
Cost-effectiveness of a mild compared with a standard strategy for IVF: a randomized comparison using cumulative term live birth as the primary endpoint
Hum. Reprod., February 1, 2008; 23(2): 316 - 323.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
H.M. Fatemi, B. Popovic-Todorovic, E. Papanikolaou, P. Donoso, and P. Devroey
An update of luteal phase support in stimulated IVF cycles
Hum. Reprod. Update, November 1, 2007; 13(6): 581 - 590.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. W. Szkudlinski
Challenges and Opportunities of Trapping Ligands
Mol. Pharmacol., August 1, 2007; 72(2): 231 - 234.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Fister, A. R. Gunthert, G. Emons, and C. Grundker
Gonadotropin-Releasing Hormone Type II Antagonists Induce Apoptotic Cell Death in Human Endometrial and Ovarian Cancer Cells In vitro and In vivo
Cancer Res., February 15, 2007; 67(4): 1750 - 1756.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
P.G. Crosignani, E. Somigliana, and on behalf of the Intrauterine Insemination (IUI) S
Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: a multicentre randomized trial
Hum. Reprod., February 1, 2007; 22(2): 500 - 505.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
E.M. Kolibianakis, J. Collins, B.C. Tarlatzis, P. Devroey, K. Diedrich, and G. Griesinger
Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis
Hum. Reprod. Update, November 1, 2006; 12(6): 651 - 671.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.